Cost-effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression

被引：3
|
作者：
Aguiar, Pedro, Jr. [1 ]
Perry, Luke A. [2 ]
Lopes, Gilberto L., Jr. [3 ]
机构：
[1] Univ Fed Sao Paulo, Oncol & Hematol Dept, Clin Oncol Sect, Sao Paulo, Brazil
[2] Monash Univ Sch Med, Fac Med Nursing & Hlth Sci, Melbourne, Vic, Australia
[3] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
来源：
LUNG CANCER MANAGEMENT | 2016年 / 5卷 / 03期
关键词：
cost-effectiveness; health technology assessment; immunotherapy; lung cancer;
D O I：
10.2217/lmt-2016-0016
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：119 / 122
页数：4
相关论文
共 50 条
  • [21] Plasma soluble PD-1/PD-L1 for prediction of prognosis in NSCLC patients treated with immune checkpoint inhibitors
    Himuro, Hidetomo
    Nakahara, Yoshiro
    Igarashi, Yuka
    Kouro, Taku
    Murakami, Shuji
    Wei, Feifei
    Horaguchi, Shun
    Tsuji, Kayoko
    Mano, Yasunobu
    Saito, Haruhiro
    Azuma, Koichi
    Sasada, Tetsuro
    CANCER SCIENCE, 2024, 115 : 1381 - 1381
  • [22] Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors
    Himuro, Hidetomo
    Nakahara, Yoshiro
    Igarashi, Yuka
    Kouro, Taku
    Higashijima, Naoko
    Matsuo, Norikazu
    Murakami, Shuji
    Wei, Feifei
    Horaguchi, Shun
    Tsuji, Kayoko
    Mano, Yasunobu
    Saito, Haruhiro
    Azuma, Koichi
    Sasada, Tetsuro
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (08) : 2829 - 2840
  • [23] Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors
    Hidetomo Himuro
    Yoshiro Nakahara
    Yuka Igarashi
    Taku Kouro
    Naoko Higashijima
    Norikazu Matsuo
    Shuji Murakami
    Feifei Wei
    Shun Horaguchi
    Kayoko Tsuji
    Yasunobu Mano
    Haruhiro Saito
    Koichi Azuma
    Tetsuro Sasada
    Cancer Immunology, Immunotherapy, 2023, 72 : 2829 - 2840
  • [24] Clinical Significance of Soluble PD-1 and PD-L1 in Plasma of NSCLC Patients Treated with Immune Checkpoint Inhibitors
    Nakahara, Y.
    Himuro, H.
    Igarashi, Y.
    Kouro, T.
    Higashijima, N.
    Matsuo, N.
    Murakami, S.
    Wei, F.
    Horaguchi, S.
    Tsuji, K.
    Mano, Y.
    Saito, H.
    Azuma, K.
    Naoki, K.
    Sasada, T.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S614 - S614
  • [25] Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint
    Magiera-Mularz, Katarzyna
    Skalniak, Lukasz
    Zak, Krzysztof M.
    Musielak, Bogdan
    Rudzinska-Szostak, Ewa
    Berlicki, Lukasz
    Kocik, Justyna
    Grudnik, Przemyslaw
    Sala, Dominik
    Zarganes-Tzitzikas, Tryfon
    Shaabani, Shabnam
    Doemling, Alexander
    Dubin, Grzegorz
    Holak, Tad A.
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2017, 56 (44) : 13732 - 13735
  • [26] Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers
    Duruisseaux, Michael
    Rouquette, Isabelle
    Adam, Julien
    Cortot, Alexis
    Cazes, Aurelie
    Gibault, Laure
    Damotte, Diane
    Lantuejoul, Sylvie
    ANNALES DE PATHOLOGIE, 2017, 37 (01) : 61 - 78
  • [27] Identifying Resistance to Checkpoint Inhibitors by Screening for PD-L1 and MHC I Expression on CTCs in NSCLC
    Leal, T.
    Schehr, J.
    Kaminski, A.
    Campbell, T.
    Traynor, A.
    Lang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S160 - S160
  • [28] PD-L1 as a biomarker of response to immune-checkpoint inhibitors
    Deborah Blythe Doroshow
    Sheena Bhalla
    Mary Beth Beasley
    Lynette M. Sholl
    Keith M. Kerr
    Sacha Gnjatic
    Ignacio I. Wistuba
    David L. Rimm
    Ming Sound Tsao
    Fred R. Hirsch
    Nature Reviews Clinical Oncology, 2021, 18 : 345 - 362
  • [29] PD-L1 as a biomarker of response to immune-checkpoint inhibitors
    Doroshow, Deborah Blythe
    Bhalla, Sheena
    Beasley, Mary Beth
    Sholl, Lynette M.
    Kerr, Keith M.
    Gnjatic, Sacha
    Wistuba, Ignacio I.
    Rimm, David L.
    Tsao, Ming Sound
    Hirsch, Fred R.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (06) : 345 - 362
  • [30] PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmare
    Zouein, Joseph
    Kesrouani, Carole
    Kourie, Hampig Raphael
    IMMUNOTHERAPY, 2021, 13 (12) : 1053 - 1065
12345